ByteDance AI Drug Discovery Spinoff Anew Labs Closes $290M Debut Round: A New Milestone in China's AI Pharma Track
Introduction: From ByteDance Internal Project to Independent AI Pharma Unicorn
On September 16, 2026, Anew Labs officially announced the completion of its debut external funding round, raising $290 million at a valuation of approximately $1.5 billion. The company was formerly ByteDance's internal AI-for-science research unit, completing its independent spinoff in June 2026 to become a standalone AI drug discovery company.
Despite completing external financing, ByteDance retains a 56% controlling stake, demonstrating the parent company's strong recognition of AI pharma's long-term strategic value. This funding is not only an important milestone in Anew Labs' development history but also the latest evidence of China's AI pharma track continuing to heat up in 2026.
Investment Lineup: Strong Endorsement from Top Institutions
This funding round was co-led by multiple top-tier venture capital institutions, with an impressive investor lineup:
Lead Investors:
- HSG (formerly Sequoia China): One of China's most influential technology investment institutions
- IDG Capital: A veteran institution with 30 years of deep investment in Chinese technology
- Hillhouse Investment: A long-term investment institution known for deep research
Follow-on Investors:
- 5Y Capital
- Gaorong Ventures
- Primavera Venture Partners
- Boyu Capital
- Shanghai Future Industries Fund (state-backed)
- SBP Group
The participation of the state-backed Shanghai Future Industries Fund reflects the Chinese government's strategic emphasis on the AI pharma track.
Four Core Technology Platforms: Building Full-Stack AI Pharma Capabilities
Anew Labs' core competitiveness lies in its four independently developed AI technology platforms, covering key stages of drug development:
1. AnewFold: Protein and Molecular Complex Structure Prediction
AnewFold is Anew Labs' flagship technology, focused on three-dimensional structure prediction of proteins and molecular complexes. Building on AlphaFold's groundbreaking work, AnewFold further optimizes prediction accuracy for drug target-related proteins, particularly excelling in protein-ligand interaction prediction.
Accurate protein structure prediction is the cornerstone of modern drug development, dramatically narrowing the search space for drug candidates and compressing traditional structural biology research that once took years into days or even hours.
2. AnewSampling: Molecular Dynamics Platform
AnewSampling focuses on molecular dynamics simulation, predicting how molecules behave dynamically in biological environments. This technology is crucial for understanding how drug molecules bind to targets and how they are metabolized in the body, helping to eliminate candidates with potential toxicity or metabolic issues during early screening stages.
3. AnewDesign: Antibody Design and Optimization
AnewDesign is a specialized tool for antibody drug development, capable of designing and optimizing antibody molecules to improve binding affinity to targets, reduce immunogenicity, and improve pharmacokinetic properties. Antibody drugs are one of the most important categories in current biopharmaceuticals, and AnewDesign's capabilities directly support Anew Labs' core pipeline projects.
4. AnewMind: Scientific Reasoning Large Language Model for Drug Discovery
AnewMind is Anew Labs' scientific reasoning large language model, specifically designed for drug development decision-making. Unlike general-purpose LLMs, AnewMind deeply integrates medicinal chemistry, pharmacology, and clinical medicine knowledge, assisting researchers in literature analysis, hypothesis generation, and R&D decision-making.
Research Pipeline: Substantive Progress from AI to Clinical
Anew Labs' research pipeline has achieved substantive progress, demonstrating that its AI technology has moved beyond proof-of-concept:
- IL-17 Target Program: A pan-IL-17 small molecule inhibitor for inflammatory diseases, which had entered the Lead Optimization stage as of mid-2026
- IL-4R Target Program: Drug candidate projects targeting allergic diseases
- Other Undisclosed Targets: Multiple projects in early discovery stages
Both IL-17 and IL-4R are validated important drug targets with massive related biologics markets. Anew Labs' choice to enter with small molecule drugs may create differentiated competitive advantages in oral administration convenience.
Strategic Independence: Why Spin Off from ByteDance?
The strategic logic for Anew Labs spinning off from ByteDance is clear:
- Capital Structure Fit: The biotech industry requires high capital investment and long development cycles, needing a company structure and financing model completely different from consumer technology
- Operational Rhythm Differences: Drug development timescales (typically 10-15 years) are completely different from ByteDance's rapidly iterating consumer products
- Talent Attraction: An independent company structure is more conducive to attracting top scientists and management talent in the biotech field
- Regulatory Compliance: An independent corporate entity helps navigate the complex regulatory requirements of the biotech industry
Despite operating independently, Anew Labs continues to leverage computing resources provided by ByteDance's cloud division, Volcano Engine, retaining important technological synergies.
Geographic Layout: Shanghai as Core, Singapore and San Jose as Wings
Anew Labs has adopted a strategic multi-location layout:
- Shanghai (Headquarters): China's most important biomedical R&D center, with abundant scientific talent and a well-developed industrial ecosystem
- Singapore: Asia-Pacific's financial and technology hub, facilitating international financing and Asia-Pacific market expansion
- San Jose (USA): Proximity to the world's top biotech ecosystem and FDA regulatory system
This layout enables Anew Labs to simultaneously serve Chinese, Asia-Pacific, and North American markets while attracting top talent globally.
Macro Context: Asia-Pacific AI Pharma Track Heating Up
Anew Labs' funding is a microcosm of the Asia-Pacific AI pharma track continuing to heat up in 2026:
- Surge in China AI Pharma Investment: In the first half of 2026, total financing in China's AI pharma sector increased by more than 150% year-on-year
- Policy Support: The Chinese government has listed AI pharma as an important component of "new quality productive forces," with multiple provinces and cities introducing special support policies
- Improved Technology Maturity: Breakthroughs in foundational technologies like AlphaFold have significantly lowered the technical barriers to AI pharma
- Intensifying Global Competition: The rapid development of international competitors like Isomorphic Labs (Google DeepMind subsidiary) and Recursion Pharmaceuticals is pushing Chinese companies to accelerate their positioning
Conclusion: China's Strength in AI Pharma
Anew Labs' successful funding demonstrates China's strong capabilities in the AI pharma field: top-tier AI technology capabilities, rich clinical data resources, a well-developed manufacturing ecosystem, and abundant capital support.
In the global AI pharma race, Chinese companies represented by Anew Labs are transitioning from followers to co-runners, with some areas already showing potential to lead. As core technologies like AnewFold continue to iterate and clinical pipelines advance, Anew Labs is poised to become an important force in the global AI pharma field in the coming years.
